HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesScenario AnalysisRegulatoryStrategyInsightsPricing

Workspace

Workspace

Free

Intelligence Active

Regunera

PMDA

Regulatory intelligence
PMDAinspection / enforcement54% confidence

[IBENTO][IBENTO]PMDA-ATC GMP Inspection Seminar 2026 applications open

Source: PMDA

Why This Matters

Why this matters: sets a inspection / enforcement precedent in the same sub-indication (cardiology) as United Therapeutics.

Regulatory Analysis

PMDA document relevant to the signal.

Supporting Context

Therapeutic area
Pulmonary Arterial Hypertension · Prostacyclin Analog
Sub-indication
Hypertension

Related signal: FDA Accepts Supplement Application for Tyvaso (Treprostinil)

Source

View source document

Related Signal

Open signal — FDA Accepts Supplement Application for Tyvaso (Treprostinil)
PrivacyTermsRefund PolicyDisclaimer

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.